These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 21191432)

  • 1. Inhaled treprostinil and pulmonary arterial hypertension.
    Nadler ST; Edelman JD
    Vasc Health Risk Manag; 2010 Dec; 6():1115-24. PubMed ID: 21191432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled treprostinil: a therapeutic review.
    Channick RN; Voswinckel R; Rubin LJ
    Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
    Ackerbauer KA; Tandon R
    J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.
    McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W
    J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
    McLaughlin VV; Palevsky HI
    Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different efficacy of inhaled and oral medications in pulmonary hypertension.
    AbuHalimeh BJ; Parambil JG; Tonelli AR
    Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Long-term experience with trerpostinil infusion treatment in patients with pulmonary arterial hypertension in the Czech Republic].
    Jansa P; Ambroz D; Maresová J; Jelínková L; Polácek P; Palecek T; Aschermann M; Linhart A
    Vnitr Lek; 2007 Apr; 53(4):333-7. PubMed ID: 17578162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
    Suleman N; Frost AE
    Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experiences with treprostinil in the treatment of pulmonary arterial hypertension.
    Stream AR; Bull TM
    Ther Adv Respir Dis; 2012 Oct; 6(5):269-76. PubMed ID: 22868690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.
    Krishnan U; Takatsuki S; Ivy DD; Kerstein J; Calderbank M; Coleman E; Rosenzweig EB
    Am J Cardiol; 2012 Dec; 110(11):1704-9. PubMed ID: 22917554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral treprostinil for the treatment of pulmonary arterial hypertension.
    de Lartigue J
    Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treprostinil for pulmonary hypertension.
    Skoro-Sajer N; Lang I; Naeije R
    Vasc Health Risk Manag; 2008; 4(3):507-13. PubMed ID: 18827901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal use of treprostinil in pulmonary arterial hypertension: a guide to the correct use of different formulations.
    Skoro-Sajer N
    Drugs; 2012 Dec; 72(18):2351-63. PubMed ID: 23231023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of treprostinil in the management of pulmonary hypertension.
    Skoro-Sajer N; Lang I
    Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.